[go: up one dir, main page]

EE200000438A - Farmatseutiliselt aktiivne morfolinool - Google Patents

Farmatseutiliselt aktiivne morfolinool

Info

Publication number
EE200000438A
EE200000438A EEP200000438A EEP200000438A EE200000438A EE 200000438 A EE200000438 A EE 200000438A EE P200000438 A EEP200000438 A EE P200000438A EE P200000438 A EEP200000438 A EE P200000438A EE 200000438 A EE200000438 A EE 200000438A
Authority
EE
Estonia
Prior art keywords
pharmaceutically active
morpholinol
active morpholinol
pharmaceutically
active
Prior art date
Application number
EEP200000438A
Other languages
English (en)
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000438A publication Critical patent/EE200000438A/et
Publication of EE04452B1 publication Critical patent/EE04452B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000438A 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine EE04452B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (2)

Publication Number Publication Date
EE200000438A true EE200000438A (et) 2001-12-17
EE04452B1 EE04452B1 (et) 2005-04-15

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000438A EE04452B1 (et) 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Country Status (30)

Country Link
US (2) US6274579B1 (et)
EP (2) EP1047428B1 (et)
JP (1) JP2002501025A (et)
KR (1) KR100568063B1 (et)
CN (2) CN1255389C (et)
AP (1) AP1229A (et)
AT (1) ATE365042T1 (et)
AU (1) AU755536B2 (et)
BR (1) BR9907203A (et)
CA (1) CA2318268A1 (et)
CY (1) CY1106828T1 (et)
DE (1) DE69936335T2 (et)
DK (1) DK1047428T3 (et)
EA (1) EA002410B1 (et)
EE (1) EE04452B1 (et)
ES (1) ES2288012T3 (et)
HR (2) HRP20051024A2 (et)
HU (1) HUP0100900A3 (et)
ID (1) ID26334A (et)
IL (2) IL161942A0 (et)
IS (1) IS2494B (et)
NO (2) NO326878B1 (et)
NZ (3) NZ505809A (et)
PL (1) PL193622B1 (et)
PT (1) PT1047428E (et)
SG (1) SG115489A1 (et)
SK (1) SK10912000A3 (et)
TR (1) TR200002126T2 (et)
WO (1) WO1999037305A1 (et)
YU (1) YU67102A (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501891A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
WO2001026641A2 (en) * 1999-10-13 2001-04-19 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ES2315525T3 (es) * 2002-08-23 2009-04-01 Eli Lilly And Company Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina.
MXPA05011557A (es) * 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
EP1678152A1 (en) * 2003-10-27 2006-07-12 Smithkline Beecham Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
MX2008008694A (es) 2006-01-03 2009-01-07 Algebra Inc Compuestos conjugados de amina terapeutica-arilsulfonamida.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
JP5952267B2 (ja) * 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
DK1047428T3 (da) 2007-10-08
BR9907203A (pt) 2000-10-17
CY1106828T1 (el) 2012-05-23
EP1829544A1 (en) 2007-09-05
NO20003721D0 (no) 2000-07-20
PT1047428E (pt) 2007-09-07
EP1047428B1 (en) 2007-06-20
AP2000001869A0 (en) 2000-09-30
EP1047428A1 (en) 2000-11-02
EA002410B1 (ru) 2002-04-25
US20020019396A1 (en) 2002-02-14
HRP20000494B1 (en) 2009-02-28
CN1294513A (zh) 2001-05-09
NZ529316A (en) 2004-05-28
NZ520349A (en) 2004-02-27
NZ505809A (en) 2002-09-27
WO1999037305A1 (en) 1999-07-29
HRP20000494A2 (en) 2000-12-31
ID26334A (id) 2000-12-14
JP2002501025A (ja) 2002-01-15
EE04452B1 (et) 2005-04-15
PL193622B1 (pl) 2007-02-28
TR200002126T2 (tr) 2000-12-21
SK10912000A3 (sk) 2001-04-09
NO20003721L (no) 2000-09-19
EP1047428A4 (en) 2001-12-19
SG115489A1 (en) 2005-10-28
AU2328099A (en) 1999-08-09
NO20083529L (no) 2000-09-19
NO326878B1 (no) 2009-03-09
PL342012A1 (en) 2001-05-07
ATE365042T1 (de) 2007-07-15
HRP20051024A2 (hr) 2006-04-30
IS5568A (is) 2000-07-20
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
DE69936335T2 (de) 2008-02-28
CN1255389C (zh) 2006-05-10
EA200000691A1 (ru) 2001-04-23
KR20010034285A (ko) 2001-04-25
CN1203858C (zh) 2005-06-01
HUP0100900A3 (en) 2002-08-28
US6391875B2 (en) 2002-05-21
IL161942A0 (en) 2005-11-20
KR100568063B1 (ko) 2006-04-07
DE69936335D1 (de) 2007-08-02
AP1229A (en) 2003-12-04
AU755536B2 (en) 2002-12-12
ES2288012T3 (es) 2007-12-16
US6274579B1 (en) 2001-08-14
YU67102A (sh) 2004-12-31
HUP0100900A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
EE200000438A (et) Farmatseutiliselt aktiivne morfolinool
PT1220856E (pt) Compostos farmaceuticamente activos
NL350038I2 (nl) Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DE69926752D1 (de) Therapeutisch wirksame biaryl-derivate
GB9823101D0 (en) Pharmaceutically active compounds
DE50007846D1 (de) Dreschkorb
DE60009395D1 (de) Bildanzeige
MA26473A1 (fr) Composes pharmacologiquement actifs.
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
NO992692L (no) Nefadozon doseringsform
NO993443D0 (no) Kabinstruktur
GB9823102D0 (en) Pharmaceutically active compounds
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DE50015795D1 (de) Sektionaltor
DE59902159D1 (de) Aktiver mikromischer
FI991568A7 (fi) Farmaseuttisesti aktiivisia trisyklisiä amiineja
NO20005769L (no) Cyklosporinderivater
DE59903807D1 (de) Wirkstoffkonzentrat
EP1157700A4 (en) ANTI-HIV SUBSTANCE
SE9802539D0 (sv) New pharmaceutically active compounds
IS8740A (is) Lyfjafræðilega virkt morfólínól
SE9700660D0 (sv) Pharmaceutically active compounds
ATA203199A (de) Ablauf
SE9704874D0 (sv) New pharmaceutically active compounds
DE60004561D1 (de) Aktive baugruppe

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130120